Kabra Drugs Limited has disclosed its audited financial results for the quarter and year ended March 31, 2026, through newspaper advertisements. The company published the results in the Free Press Journal, an English daily, and Navbharat, a Hindi regional language newspaper, to comply with regulatory requirements.

The disclosure was submitted to BSE Limited on June 3, 2026, pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing was signed by Nanjappan Aravind, Managing Director, confirming the dissemination of the financial extract.

The company's BSE scrip code is 524322. The advertisement provided an extract of the audited financial results, ensuring the information is available to the public and shareholders in both English and Hindi.

Kabra Drugs Limited has scheduled a meeting of its Board of Directors for May 29, 2026. The meeting will be held at the company's Corporate Office in Chennai. The primary agenda for the gathering is to consider and approve the unaudited financial results for the quarter ended March 31, 2026.

The board will review the performance of the company for the fourth quarter of the fiscal year 2026. This approval is pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Additionally, the directors may discuss any other business with the permission of the chair.

In conjunction with the upcoming financial announcement, the company has closed the trading window for dealing in its shares. This restriction applies to all promoters, directors, designated employees, and concerned connected persons. The window will remain closed until 48 hours after the financial results are officially announced to the exchanges.

The intimation regarding the board meeting was submitted to BSE Limited on May 21, 2026. The company operates under the CIN L02423MP1989PLC005438 and is registered at its office in Indore, Madhya Pradesh.